eye drops

Can cannabis succeed where other compounds have failedUse of a novel semi-fluorinated alkane drug delivery technology as a vehicle to deliver cannabinoids to the ocular surface reached target tissues without systemic side effects in preclinical studies.
New eye drop assistant helps drive complianceAs ODs, we are fully aware of the challenge patient compliance with prescribed eye drops. To assuage the battle of compliance, eye drop manufacturers are assiduously working to devise drug delivery systems that reduce or eliminate patients’ engagement in the instillation of their prescribed therapy. But until ODs no longer use eye drops, drops remain our primary mode of drug delivery.
How to instill eye drops and avoid contaminationEye drops and ointments are prescribed by doctors to treat acute or long-term ocular conditions. Drops and ointments are administered directly in the site of action and are therefore very effective in treating the diagnosed condition.
The effect of drug pricing on cataract surgeryIn a recent wave of drug price increases that can only be explained by pharmaceutical manufacturers’ desire for profit maximization and which doctors and patients may call price gouging, the drug price war has been brought to the doorsteps of many eyecare providers. As optometrists are increasing their practice of medical optometry, patients are now calling their doctors about prior authorizations and unaffordable drug copays.
Compounding pharmacy recalls medicationsAbbott's Compounding Pharmacy in Berkeley, Calif., is voluntarily recalling all unexpired lots of sterile compounded products because of lack of sterility assurance.
2015's glaucoma therapy advancesWhile no new drug shook up the world of glaucoma in 2015, a variety of promising agents made incremental advances toward the market with their true potential as yet unproven. Manufacturers have continued to refine approaches to existing drugs.
ROCK inhibitors show promise in glaucoma treatmentA novel class of drugs ‒ rho-kinase, or ROCK inhibitors ‒ appears to lower IOP by relaxing the trabecular meshwork.
Acute migraine sufferers may find relief with beta-blocker eye dropsA small case series of patients has shown that use of beta-blocker drops may be a simple and inexpensive way to eliminate pain in patients with acute migraines.
Treating dry eye with lipid-based eye dropsThe lipid layer prevents evaporation of aqueous tears and prevents drying. Lipid deficiency due to meibomian gland dysfunction (MGD) is the most common cause of symptoms associated with dry eye disease.
The dexamethasone nanowafer: A novel method of drug delivery for dry eye diseaseThis review presents a therapeutic nanowafer as an alternative to eye drops for dry eye disease, designed to enhance efficacy and improve patient compliance to treatment. In an experimental animal study, the novel dexamethasone nanowafer drug delivery system was comparable in efficacy to twice-daily dexamethasone eye drop treatment and has the potential to minimise risk of cataract formation and glaucoma.